• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

New Era for Renal-Protective Therapy in Type 2 Diabetes: Better Renal Outcomes in Patients with Type 2 Diabetes Taking Sodium-Glucose Cotransporter 2 Inhibitors versus Dipeptidyl Peptidase-4 Inhibitors.

作者信息

Jung Chan-Hee

机构信息

Division of Endocrinology and Metabolism, Department of Internal Medicine, Soonchunhyang University Bucheon Hospital, Soonchunhyang University College of Medicine, Bucheon, Korea.

出版信息

Endocrinol Metab (Seoul). 2021 Apr;36(2):339-341. doi: 10.3803/EnM.2021.203. Epub 2021 Apr 27.

DOI:10.3803/EnM.2021.203
PMID:33934589
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8090473/
Abstract
摘要

相似文献

1
New Era for Renal-Protective Therapy in Type 2 Diabetes: Better Renal Outcomes in Patients with Type 2 Diabetes Taking Sodium-Glucose Cotransporter 2 Inhibitors versus Dipeptidyl Peptidase-4 Inhibitors.2型糖尿病肾脏保护治疗的新时代：2型糖尿病患者服用钠-葡萄糖协同转运蛋白2抑制剂与二肽基肽酶-4抑制剂相比，肾脏结局更佳。
Endocrinol Metab (Seoul). 2021 Apr;36(2):339-341. doi: 10.3803/EnM.2021.203. Epub 2021 Apr 27.
2
Comment on "Comparison of Sodium-Glucose Cotransporter-2 Inhibitor and Dipeptidyl Peptidase-4 Inhibitor on the Risks of New-Onset Atrial Fibrillation, Stroke and Mortality in Diabetic Patients".关于“钠-葡萄糖协同转运蛋白2抑制剂与二肽基肽酶-4抑制剂对糖尿病患者新发房颤、中风及死亡风险的比较”的评论
Cardiovasc Drugs Ther. 2024 Feb;38(1):201-202. doi: 10.1007/s10557-023-07527-z. Epub 2023 Nov 27.
3
Risk of hospitalization with sodium-glucose cotransporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes lacking evidence of chronic kidney disease: Real-world data.2型糖尿病且无慢性肾脏病证据患者中，钠-葡萄糖协同转运蛋白2抑制剂与二肽基肽酶-4抑制剂相比的住院风险：真实世界数据
Diabetes Obes Metab. 2023 Oct;25(10):3054-3058. doi: 10.1111/dom.15172. Epub 2023 Jun 29.
4
Cardiorenal benefits of sodium-glucose co-transporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors in type 2 diabetes without cardiovascular and renal diseases.在无心血管和肾脏疾病的2型糖尿病患者中，钠-葡萄糖协同转运蛋白2抑制剂与二肽基肽酶-4抑制剂的心脏肾脏获益比较
Diabetes Obes Metab. 2022 Mar;24(3):575-577. doi: 10.1111/dom.14588. Epub 2021 Nov 15.
5
Dipeptidyl peptidase-4 inhibitors and gallbladder or biliary disease in type 2 diabetes: systematic review and pairwise and network meta-analysis of randomised controlled trials.二肽基肽酶-4 抑制剂与 2 型糖尿病患者的胆囊或胆道疾病：系统评价及随机对照试验的两两和网络荟萃分析。
BMJ. 2022 Jun 28;377:e068882. doi: 10.1136/bmj-2021-068882.
6
Effectiveness and safety of sodium-glucose co-transporter-2 inhibitors compared with dipeptidyl peptidase-4 inhibitors in older adults with type 2 diabetes: A nationwide population-based study.钠-葡萄糖共转运蛋白 2 抑制剂与二肽基肽酶-4 抑制剂在老年 2 型糖尿病患者中的疗效和安全性比较：一项全国性基于人群的研究。
Diabetes Obes Metab. 2021 Mar;23(3):682-691. doi: 10.1111/dom.14261. Epub 2020 Dec 15.
7
Bullous pemphigoid associated with use of dipeptidyl peptidase-4 inhibitor.与使用二肽基肽酶-4抑制剂相关的大疱性类天疱疮。
CMAJ. 2022 May 24;194(20):E705. doi: 10.1503/cmaj.211933.
8
Cost-effectiveness of sodium-glucose cotransporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors among patients with type 2 diabetes with and without established cardiovascular diseases: A model-based simulation analysis using 10-year real-world data and targeted literature review.钠-葡萄糖共转运蛋白 2 抑制剂与二肽基肽酶-4 抑制剂在伴有和不伴有已确立心血管疾病的 2 型糖尿病患者中的成本效益：基于模型的模拟分析，使用 10 年真实世界数据和有针对性的文献回顾。
Diabetes Obes Metab. 2022 Jul;24(7):1328-1337. doi: 10.1111/dom.14708. Epub 2022 Apr 26.
9
Sodium-glucose co-transporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors and the risk of heart failure: A nationwide cohort study of older adults with diabetes mellitus.钠-葡萄糖协同转运蛋白 2 抑制剂与二肽基肽酶-4 抑制剂治疗糖尿病与心力衰竭风险：一项全国性老年糖尿病患者队列研究
Diabetes Obes Metab. 2021 Apr;23(4):950-960. doi: 10.1111/dom.14300. Epub 2021 Jan 13.
10
Lower risk of hospitalization for heart failure, kidney disease and death with sodium-glucose co-transporter-2 inhibitors compared with dipeptidyl peptidase-4 inhibitors in type 2 diabetes regardless of prior cardiovascular or kidney disease: A retrospective cohort study in UK primary care.钠-葡萄糖共转运蛋白 2 抑制剂与二肽基肽酶-4 抑制剂相比，在 2 型糖尿病患者中无论是否存在心血管或肾脏疾病，均可降低心力衰竭、肾脏疾病和死亡的住院风险：英国初级保健中的一项回顾性队列研究。
Diabetes Obes Metab. 2021 Oct;23(10):2207-2214. doi: 10.1111/dom.14437. Epub 2021 Aug 2.

本文引用的文献

1
Comparative Renal Effects of Dipeptidyl Peptidase-4 Inhibitors and Sodium-Glucose Cotransporter 2 Inhibitors on Individual Outcomes in Patients with Type 2 Diabetes: A Systematic Review and Network Meta-Analysis.比较二肽基肽酶-4 抑制剂和钠-葡萄糖协同转运蛋白 2 抑制剂对 2 型糖尿病患者个体结局的肾脏影响：系统评价和网络荟萃分析。
Endocrinol Metab (Seoul). 2021 Apr;36(2):388-400. doi: 10.3803/EnM.2020.912. Epub 2021 Mar 31.
2
Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease: a prespecified analysis from the DAPA-CKD trial.达格列净对伴有和不伴有糖尿病的慢性肾脏病患者的主要不良肾脏和心血管事件的影响：来自 DAPA-CKD 试验的预先指定分析。
Lancet Diabetes Endocrinol. 2021 Jan;9(1):22-31. doi: 10.1016/S2213-8587(20)30369-7.
3
9. Pharmacologic Approaches to Glycemic Treatment: .9. 血糖治疗的药物学方法： 。
Diabetes Care. 2021 Jan;44(Suppl 1):S111-S124. doi: 10.2337/dc21-S009.
4
Renoprotection with SGLT2 inhibitors in type 2 diabetes over a spectrum of cardiovascular and renal risk.在 2 型糖尿病的一系列心血管和肾脏风险中，SGLT2 抑制剂的肾脏保护作用。
Cardiovasc Diabetol. 2020 Nov 22;19(1):196. doi: 10.1186/s12933-020-01163-9.
5
Cardiorenal Protection With the Newer Antidiabetic Agents in Patients With Diabetes and Chronic Kidney Disease: A Scientific Statement From the American Heart Association.新型抗糖尿病药物在糖尿病合并慢性肾脏病患者中的心脏肾脏保护作用：美国心脏协会的科学声明。
Circulation. 2020 Oct 27;142(17):e265-e286. doi: 10.1161/CIR.0000000000000920. Epub 2020 Sep 28.
6
Executive summary of the 2020 KDIGO Diabetes Management in CKD Guideline: evidence-based advances in monitoring and treatment.2020年KDIGO慢性肾脏病糖尿病管理指南执行摘要：监测与治疗方面基于证据的进展
Kidney Int. 2020 Oct;98(4):839-848. doi: 10.1016/j.kint.2020.06.024. Epub 2020 Jul 10.
7
2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD.2019年欧洲心脏病学会（ESC）与欧洲糖尿病研究协会（EASD）合作制定的糖尿病、糖尿病前期和心血管疾病指南。
Eur Heart J. 2020 Jan 7;41(2):255-323. doi: 10.1093/eurheartj/ehz486.
8
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy.卡格列净与 2 型糖尿病和肾病患者的肾脏结局。
N Engl J Med. 2019 Jun 13;380(24):2295-2306. doi: 10.1056/NEJMoa1811744. Epub 2019 Apr 14.
9
Diabetes Fact Sheet in Korea, 2016: An Appraisal of Current Status.《2016年韩国糖尿病情况说明书：现状评估》
Diabetes Metab J. 2018 Oct;42(5):415-424. doi: 10.4093/dmj.2018.0017. Epub 2018 Aug 9.
10
Renal Effects of Incretin-Based Diabetes Therapies: Pre-clinical Predictions and Clinical Trial Outcomes.基于肠降血糖素的糖尿病治疗药物的肾脏效应：临床前预测和临床试验结果。
Curr Diab Rep. 2018 Apr 13;18(5):28. doi: 10.1007/s11892-018-0991-7.